New US/Private Collaboration Aims at Accurate Treatment of Heart Failure

Picture of a heart with a double helix in front of the DNA to indicate genetic heart diseases such as familial hypercholesterolemia.
Credit: iStock/SvetaP DNA double helix: iStock/Kagenmi

A new partnership to study heart failure with preserved ejection fraction (HFpEF) has been launched by the National Institutes of Health and several private companies. The National Institutes of Health (FNIH) Foundation and the National Heart, Lung, and Blood Institute (NHLBI) will work with partners including Bayer US, Cytokinetics, Ionis Pharmaceuticals, Novartis AG, and Ultromics.

The point of Accelerate Heart Failure Drug Partnership The AMP HF Program aims to develop precise treatment strategies for HFpEF. It collects resources Eight partner organizations Covering both the public and private sectors, with total commitments in excess of $37 million. FNIH will provide project management for the effort over the next five years.

Approximately half of heart failure patients have HFpEF. Understanding what it is, when it occurs, and how to treat it remains the single greatest unmet need in cardiovascular health. The AMP HF program aims to bridge this gap in understanding and ultimately improve the lives of patients everywhere,” said Norman Stockbridge, MD, director of the division of cardiology and nephrology in the Office of Cardiology, Hematology, Endocrinology, and Nephrology at the U.S. Food and Drug Administration (FDA). ).

Using the latest technology, including digital measurements and artificial intelligence analysis methods, the new program is designed to find new proteins or genes that can mitigate this disease when altered by treatments.

Lawrence A. said: Tabak, MD, PhD, performs the duties of Director of the National Institutes of Health. “AMP Heart Failure aims to improve the odds of hitting the mark early and quickly.”

Although convincing progress has been made in treating many heart diseases, deaths from heart failure continue to rise nationally. In the United States alone, heart failure directly contributes to about 45% of all cardiovascular disease deaths.

“AMP Heart Failure — and a high level of partnership at its core — will help us better understand and treat this common syndrome with the goal of ultimately benefiting millions,” said NHLBI Director Gary H.

HFpEF is a common form of heart failure in which the ejection fraction – the percentage of blood ejected from the left ventricle with each heartbeat – is within the normal range. HFpEF is difficult to detect, because the left ventricle appears to function normally, and is often fatal, with a five-year survival rate of only 35-40%. In addition to a higher risk of death, HFpEF patients have a deteriorating quality of life and an impaired ability to perform tasks of daily living.

The AMP HF Programme, a public-private partnership facilitated by FNIH, will advance our understanding of heart failure with preserved ejection fraction using two complementary and complementary research components: analysis of existing HFpEF data sets, drawn from publicly and privately funded studies, and initiation of a new clinical trial to confirm findings retrospectively. In an observational group with the goal of developing a framework for novel microtherapies.

“HFpEF is clearly a major cause of in-hospital heart failure and deteriorating quality of life for older patients. To date, it has eluded us to develop effective therapeutic strategies to identify and treat HFpEF. Through AMP HF, we will benefit from the valuable perspectives and experience that collaborations bring to biomedical research. paving the way for a more optimistic outlook,” said Julie Gerberding, chief executive officer at FNIH.

Leave a Comment